Table 2:
DMARDs used for the treatment of IA
| Drug/Drug class | Efficacy in RA? | Efficacy in SpA? | Use in ICI-IA? |
|---|---|---|---|
| Hydroxychloroquine | Yes | No | Yes |
| Sulfasalazine | Yes | Yes (peripheral arthritis only) | Yes |
| Methotrexate | Yes | Yes (peripheral arthritis only) | Yes |
| Leflunomide | Yes | Yes (PsA) | Yes |
| Apremilast (PDE4 inhibitor) | No | Yes (PsA) | Not reported (use in PsO only) |
| Abatacept (CTLA-4 Agonist, CTLA4-Ig) | Yes | Yes (PsA) | Not reported |
| TNF-inhibitors | Yes | Yes (axial and peripheral arthritis) | Yes |
| IL-6 inhibitors | Yes | No | Yes |
| IL-12/23 inhibitor | No | Yes (PsA) | Not reported (use in PsO only) |
| IL-17 Inhibitors | No | Yes (axial and peripheral) | Not reported |
| JAK-Inhibitors | Yes | Yes-PsA | Not reported |
| Rituximab (Anti-CD20 antibody) | Yes | No | Not reported |
RA (rheumatoid arthritis); SpA (spondyloarthritis); ICI-IA (immune checkpoint inhibitor-induced inflammatory arthritis); PsA (psoriatic arthritis); PsO (psoriasis without arthritis); DMARD (disease modifying anti-rheumatic drug); PDE4 (phosphodiesterase 4); CTLA-4 (cytotoxic T-lymphocyte-associated protein 4); TNF (tumor necrosis factor); IL (interleukin); JAK (janus kinase)